Clinical and Biochemical Characteristics Differentiating Chronic Fatigue Syndrome from Major Depression and Healthy Control Populations

References

• Holmes GP, Kaplan JE, Glantz, NM et al. Chronic fatigue syndrome: A working case definition. Ann Intern Med 1988; 108: 387–389.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Straus SE, Hickie I et al. The chronic fatigue syndrome: A compre-hensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med 1994; 121:953–959.
   PubMed Web of Science ®Google Scholar
• Jason LA, Richman JA, Rademaker AW et al. A community-based study of chronic fatigue syndrome. Arch Intern Med 1999; 159:2129–2137.
   PubMed Web of Science ®Google Scholar
• Reyes M, Nisenbaum R, Hoaglin DC et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003; 163:1530–1536.
   PubMed Web of Science ®Google Scholar
• Chao CC, Janoff EN, Hu SX et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991; 3:292–298.
   PubMed Web of Science ®Google Scholar
• Levy JA. Viral studies of chronic fatigue syndrome. CIM Infect Dis 1994; 18:S117–S120.
   PubMed Web of Science ®Google Scholar
• Straus S, Fritz S, Dale J et al. Lymphocyte phenotype and function in the chronic fatigue syndrome. J CIM Immunol 1993; 13:30–40.
   Web of Science ®Google Scholar
• Caliguiri M, Murray C, Buchwald D et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139:3306–3313.
   PubMed Web of Science ®Google Scholar
• Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J CIM Microbiol 1990; 28:1403–1410.
   Web of Science ®Google Scholar
• Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. CIM Exp Immunol 1992; 87:76–79.
   Google Scholar
• Komaroff AL, Buchwald DS. Chronic fatigue syndrome: An update. Ann Rev Med 1998; 49:1–13.
   PubMed Web of Science ®Google Scholar
• Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M. A study of the immunol-ogy of the chronic fatigue syndrome: Correlation of immunologic parameters to health dysfunction. CIM Immunol Immunopathol 1998; 87:60–67.
   Google Scholar
• Patarca-Montero R, Mark T, Fletcher MA, Klimas NG. Immunology of chronic fatigue syndrome. J Chron Fat Syndr 2000; 6:69–108.
   Google Scholar
• Patarca-Montero R. Cytokines and chronic fatigue syndrome. Ann NY Acacl Sci 2001; 933:185–200.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 1998; 105:27S–34S.
   Google Scholar
• Ogawa M, Nishiura T, Yoshimura Metal. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. Eur J CIM Invest 1998; 28:937–943.
   Google Scholar
• Lengyel P. Biochemistry of interferons and their actions. Annu Review Biochem 1982; 51:251–282.
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IIV1, Williams BR, Silverman RH, Schreiber RD. Annu Rev Biochem 1998; 67:227–264.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. CIM Infectious Dis 1994; 18:S96–S104.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges Petal. Changes in the 2-5A synthetase/ RNase L antiviral pathway in a controlled clinical trial with poly(I)- poly(C12U) in chronic fatigue syndrome. In Vivo 1994; 8:599–604.
   Google Scholar
• Suhadolnik RJ, Peterson DL, O'Brien K et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Inter-feron & Cytokine Res 1997; 17:377–385.
   Google Scholar
• Shetzline SE, Suhadolnik RJ. Characterization of a 2',5' - oligoadenylate (2-5A)-dependent 37-kDa RNase L. Azido photoaffinity labeling and 2-5A-dependent activa-tion. J Biol Chem 2001; 276:23707–23711.
   Google Scholar
• Shetzline SE, Martinand-Mari C, Reichenbach NL et al. Structural and func-tional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon & Cytokine Res 2002; 22:443–456.
   PubMed Web of Science ®Google Scholar
• De Meirleir K, Bisbal C, Campine I et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108:99–105.
   PubMed Web of Science ®Google Scholar
• McGregor NR, Dunstan RH, Niblett SH et al. The biochemistry of chronic pain and fatigue. J Chron Fat Syndr 2000; 7(1):3–21.
   Google Scholar
• Snell CR, Van Ness TM, Strayer DR, Stevens SR. Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo 2002; 16:107–110.
   PubMed Web of Science ®Google Scholar
• Demettre E, Bastide L, D'Haese A et al. Ribonuclease L proteolysis in periph-eral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 2002; 277:35746–35751.
   Google Scholar
• Tiev KP, Demettre E, Ercolano P et al. RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kalodalton isoform ratio is a potential test for chronic fatigue syndrome. Clin Diag Lab Immunol 2003; 10:315–316.
   PubMedGoogle Scholar
• Vojdani A, Choppa PC, Lapp CW. Downregulation of RNase L inhibitor corre-lates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome. J Clin Lab Immunol 1998; 50:1–16.
   Google Scholar
• Englebienne P, De Meirleir K (eds.). Chronic fatigue syndrome. A biological approach. Boca Raton, FL, CRC Press, 2002.
   Google Scholar
• Diagnostic and statistical manual of mental disorders (DSM-IIIR). 3rd edition. Washington, DC: American Psychiatric Association Press, 1987.
   Google Scholar
• Ware JE JR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473–483.
   Google Scholar
• Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individu-als. Am J Med 1996; 171:364–370.
   Google Scholar
• Cornell Medical Index Health Questionnaire, Cornell University Medical Col-lege, New York, 1974.
   Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.
   PubMed Web of Science ®Google Scholar
• Schag CC, Heinrich RL, Ganz PA. Karnofsky performance revisited: Reliabil-ity, validity, and guidelines. J ClM Oncol 1984; 2:187–193.
   Google Scholar
• Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J ClM Microbiol 1990; 28:1403–1410.
   PubMed Web of Science ®Google Scholar
• Komaroff AL. The biology of chronic fatigue syndrome. Am J Med 2000; 108:169–171.
   PubMed Web of Science ®Google Scholar
• Vernon SD, Unger ER, Dimulescu IIV1, Rajeevan M, Reeves WC. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syn-drome. Dis Markers 2002; 18:193–199.
   Google Scholar
• Arend WP. Mediators of inflammation, tissue destruction, and repair. Growth factors and cytokines. In: Primer on the rheumatic diseases, 12th ed., 2001; pp. 58–66. Arthritis Foundation, Atlanta.
   Google Scholar
• Dantzer R, Bluthe RM, Aubert A, Goodall G, Bret-Dibat IL et al. Cytokine ac-tions on behavior. In: Cytokines in the nervous system (Rothwell, NJ, Ed.), 1996; pp. 117–144. R. G. Landes Company and Chapman & Hall, New York.
   Google Scholar
• Feldman M, Brenan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397–440.
   PubMed Web of Science ®Google Scholar
• Steinke JW, Borish L. Th2 cytokines and asthma-Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 recep-tor antagonists. Respir Res 2001; 2:66–70.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Peterson DL, Cheney PR et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. J Chron Fat Synd 1999; 5:223–242.
   Google Scholar
• Gow JWK, Simpson K, Behan PO et al. Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. ClM Infect Dis 2001; 33:2080–2081.
   PubMed Web of Science ®Google Scholar
• Hickie I, Lloyd A, Wafefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry 1990; 156:534–540.
   PubMed Web of Science ®Google Scholar
• Abbey SE, Garfinkel PE. Chronic fatigue syndrome and depression: Cause, ef-fect, or covariate. Rev Infect Dis 1991; 13: S73–S78.
   Google Scholar
• Natelson BH, Johnson SK, DeLuca J et al. Reducing heterogeneity in chronic fatigue syndrome: A comparison with depression and multiple sclerosis. ClM Infect Dis 1995; 21:1204–1210.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Fagioli LR, Doolittle TH et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996; 101:281–290.
   PubMed Web of Science ®Google Scholar
• Johnson SK, DeLuca J, Natelson BH. Depression in fatiguing illness: Compar-ing patients with chronic fatigue syndrome, multiple sclerosis and depression. J Affect Disord 1996; 39:21–30.
   Google Scholar
• Roy-Bume P, Afari N, Ashton S et al. Chronic fatigue and anxiety/depression: A twin study. Br J Psychiatry 2002; 180:29–34.
   PubMed Web of Science ®Google Scholar
• Hardt J, Buchwald D, Wilks D et al. Health-related quality of life in patients with chronic fatigue syndrome. An international study. J Psychosomatic Res 2001; 51:431–434.
   PubMed Web of Science ®Google Scholar
• Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Medical Hypotheses 2000; 54:115–125.
   PubMed Web of Science ®Google Scholar
• Bastien S. Patterns of neuropsychological abnormalities and cognitive impair-ment in adults and children. In: The clinical and scientific basis of myalgic encephalomyelitis/chronic fatigue syndrome. Hyde B, Goldstein J, Levine P (eds.), 1992; pp. 453–460. Nightingale Research Foundation, Ottawa, Canada.
   Google Scholar
• Scheffers MK, Johnson R Jr, Grafman J, Dale JK, Straus SE. Attention and short-term memory in chronic fatigue syndrome patients: an event-related potential analysis. Neurology 1992; 42: 1667–1675.
   PubMed Web of Science ®Google Scholar
• Marcel B, Komaroff AL, Fagioli LR, Komish RJ 2nd, Albert MS. Cognitive deficits in patients with chronic fatigue syndrome. Biol Psychiatry 1996; 40:535–541.
   Google Scholar
• DeLuca J, Johnson SK, Ellis SP, Natelson BH. Cognitive functioning is im-paired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry 1997; 62: 151–155.
   PubMed Web of Science ®Google Scholar
• Christodoulou C, DeLuca J, Lange G et al. Relation between neuropsycho-logical impairment and functional disability in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1998; 64: 431–434.
   PubMed Web of Science ®Google Scholar
• Toccaceli F, Rosati S, Scuderi Metal. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45: 1748–1752.
   Google Scholar
• Oreffo RO, Romberg S, Virdi AS et al. Effects of interferon alpha on human osteoprogenitor cell growth and differentiation in vitro. J Cell Biochem 1999; 74: 372–385.
   PubMed Web of Science ®Google Scholar
• Tsuda-Futami E, Shioi A, Jono S et al. Lymphoblastoid interferon-alpha downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor ex-pression in human osteoblastic cells (Saos-2). Bone 1998; 23: 205–211.
   PubMed Web of Science ®Google Scholar
• Sillaber C, Geissler K, Scherrer R et al. Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. Blood 1993; 80: 634–641.
   Web of Science ®Google Scholar
• Yamagata T, Miura N, Hirai K, Kurokawa K, Higashihara M. Natural inter-feron-alfa for basophilia. Br J Haematol 1992; 82: 780–781.
   Google Scholar
• Corssmit EP, Heijligenberg R, Hack CE et al. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 1997; 107:359–363.
   PubMed Web of Science ®Google Scholar
• Gyllenhammar H, Hafstrom I, Ringertz B, Uden AM, Palmblad J. Recombinant human leukocyte interferon modulates neutrophil function in vitro. J Interferon Res 1988; 8:441–449.
   Google Scholar
• Schomburg A, Kirchner H, Atzpodien J. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: Evidence of a risk/benefit advan-tage of subcutaneous therapy. J Cancer Res Clin Oncol 1993; 119:745–755.
   Google Scholar
• Matsuo T, Takabatake R. Multiple sclerosis-like disease secondary to alpha in-terferon. Ocul Immunol Inflamm 2002; 10: 299–304.
   PubMed Web of Science ®Google Scholar
• Kennedy G, Spence VA, Underwood C, McLaren M, Belch JJF. Increased neutrophil apoptosis in chronic fatigue syndrome. J Thrombosis & Haemostasis 2003; 1 (Supplement 1): P1258.
   Google Scholar